Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SNRNP200 | O75643 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10672127 | 0.82 | ACHE (0.62) | MAPK1MAPK3ACHEEPHX2DDB1 | |
| SCHEMBL13606951 | 0.82 | KDM4E (0.47) | MAPK1MAPK3ACHEEPHX2DDB1 | |
| SCHEMBL13382916 | 0.80 | MAPK1 (0.48) | MAPK1MAPK3ACHEEPHX2DDB1 | |
| SCHEMBL27790555 | 0.80 | CA9 (0.49) | CRBNCA9KDM4EMEN1GAA | |
| SCHEMBL3596541 | 0.79 | MAPK1 (0.47) | MAPK1MAPK3ACHEEPHX2DDB1 | |
| SCHEMBL3600321 | 0.78 | CA9 (0.47) | CA9KDM4EALDH1A1HPGD | |
| SCHEMBL29010959 | 0.77 | KDM4E (0.55) | ACHECRBNKDM4EMEN1KMT2A | |
| SCHEMBL31391661 | 0.77 | KDM4E (0.55) | ACHECRBNKDM4EMEN1KMT2A | |
| SCHEMBL29546562 | 0.75 | MAPK1 (0.55) | MAPK1MAPK3ACHEEPHX2DDB1 | |
| SCHEMBL3225584 | 0.74 | GRM5 (0.49) | ACHEKDM4EMEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| CN-101589038-A | Heterocyclidene-N-(aryl)acetamide derivative | MOCHIDA PHARM CO LTD (JP) | 2009-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | MAPK1 1102/4885MAPK3 485/4885ACHE 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.